Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-5-6
|
pubmed:abstractText |
In the present study the effect of mizolastine (CAS 108612-45-9, SL85.0324-00) a novel potent histamine H1-receptor antagonist, on 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis, a rat model of inflammatory bowel disease, was investigated to determine whether mizolastine has anti-inflammatory properties. Treatment with TNBS resulted in increased nociception in response to rectal balloon distension and caused intestinal damage, tissue oedema and inflammation. Oral mizolastine (0.03-3.00 mg/kg given 1 h before and once daily for 3 days after TNBS treatment) significantly (p < 0.05) reduced nociception (49% at 0.3 mg/kg), gross intestinal damage (78% at 3.0 mg/kg), histological damage (54% at 3.0 mg/kg), intestinal tissue weight (69% at 3.0 mg/kg) and myeloperoxidase activity (66% at 3.0 mg/kg). In contrast, the H1-receptor antagonist terfenadine tested under the same experimental conditions at 3-30 mg/kg was without significant effect. It is concluded that, in addition to its antiallergic properties, mizolastine possesses anti-inflammatory actions that may not be related to its H1-receptor blocking properties, reducing sensory afferent hypersensitivity, damage and neutrophil infiltration observed during colitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H1 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Peroxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Terfenadine,
http://linkedlifedata.com/resource/pubmed/chemical/Trinitrobenzenesulfonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/mizolastine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
179-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9541730-Animals,
pubmed-meshheading:9541730-Benzimidazoles,
pubmed-meshheading:9541730-Colitis,
pubmed-meshheading:9541730-Colon,
pubmed-meshheading:9541730-Histamine H1 Antagonists,
pubmed-meshheading:9541730-Hypersensitivity,
pubmed-meshheading:9541730-Male,
pubmed-meshheading:9541730-Neurons, Afferent,
pubmed-meshheading:9541730-Organ Size,
pubmed-meshheading:9541730-Peroxidase,
pubmed-meshheading:9541730-Rats,
pubmed-meshheading:9541730-Rats, Wistar,
pubmed-meshheading:9541730-Terfenadine,
pubmed-meshheading:9541730-Trinitrobenzenesulfonic Acid
|
pubmed:year |
1998
|
pubmed:articleTitle |
Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis.
|
pubmed:affiliation |
Synthélabo Recherche, Rueil-Malmaison France.
|
pubmed:publicationType |
Journal Article,
In Vitro
|